| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2006;114:1608-1615.)
© 2006 American Heart Association, Inc.
Transplantation |
From the Departments of Pediatrics (W.T., P.S.-B., L.L., K.Y.D., C.C., D.B.L.), Cardiovascular Medicine (L.P., H.L., W.F.F., J.P.C., H.A.V.), Health Research and Policy (T.H.H.), and Microbiology and Immunology (E.S.M.), and the Program in Immunology (D.B.L.), Stanford University School of Medicine, Stanford, Calif.
Correspondence to David B. Lewis, MD, Division of Immunology and Transplantation Biology, Department of Pediatrics, CCSR Bldg, Room 2115b, 269 Campus Dr, Stanford University School of Medicine, Stanford, CA 94305-5164. E-mail dblewis{at}stanford.edu
Received December 10, 2005; revision received June 19, 2006; accepted July 13, 2006.
Background Asymptomatic cytomegalovirus (CMV) replication is frequent after cardiac transplantation in recipients with pretransplantation CMV infection. How subclinical viral replication influences cardiac allograft disease remains poorly understood, as does the importance of T-cell immunity in controlling such replication.
Methods and Results Thirty-nine cardiac recipients who were pretransplantation CMV antibody positive were longitudinally studied for circulating CMV-specific CD4 and CD8 T-cell responses, CMV viral load in blood neutrophils, and allograft rejection during the first posttransplantation year. Nineteen of these recipients were also analyzed for changes of coronary artery intimal, lumen, and whole-vessel area. All recipients received early prophylactic therapy with ganciclovir. No recipients developed overt CMV disease. Those with detectable levels of CMV-specific CD4 T cells in the first month after transplantation were significantly protected from high mean and peak posttransplantation viral load (P<0.05), acute rejection (P<0.005), and loss of allograft coronary artery lumen (P<0.05) and of whole-vessel area (P<0.05) compared with those who lacked this immune response. The losses of lumen and vessel area were both significantly correlated with the time after transplantation at which a CD4 T-cell response was first detected (P<0.05) and with the cumulative graft rejection score (P<0.05).
Conclusions The early control of subclinical CMV replication after transplantation by T-cell immunity may limit cardiac allograft rejection and vascular disease. Interventions to increase T-cell immunity might be clinically useful in limiting these adverse viral effects.
This article has been cited by other articles:
![]() |
J. Simmonds, M. Fenton, C. Dewar, E. Ellins, C. Storry, D. Cubitt, J. Deanfield, N. Klein, J. Halcox, and M. Burch Endothelial Dysfunction and Cytomegalovirus Replication in Pediatric Heart Transplantation Circulation, May 20, 2008; 117(20): 2657 - 2661. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Stern and B. Slobedman Human Cytomegalovirus Latent Infection of Myeloid Cells Directs Monocyte Migration by Up-Regulating Monocyte Chemotactic Protein-1 J. Immunol., May 15, 2008; 180(10): 6577 - 6585. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Schmauss and M. Weis Cardiac Allograft Vasculopathy: Recent Developments Circulation, April 22, 2008; 117(16): 2131 - 2141. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Potena, C. T. J. Holweg, M. L. Vana, L. Bashyam, J. Rajamani, A. L. McCormick, J. P. Cooke, H. A. Valantine, and E. S. Mocarski Frequent Occult Infection with Cytomegalovirus in Cardiac Transplant Recipients despite Antiviral Prophylaxis J. Clin. Microbiol., June 1, 2007; 45(6): 1804 - 1810. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Tellides Th1 Adaptive Immune Responses in Cardiac Graft Arteriosclerosis: Deleterious or Beneficial? Circulation, October 10, 2006; 114(15): 1561 - 1564. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |